IKT 外汇新闻
Inhibikase Says FDA Clears IND For IkT-001Pro To Treat Chronic Myelogenous Leukemia
Pharmaceutical company Inhibikase Therapeutics, Inc. (IKT) announced Friday that the U.S. Food and Drug Administration (FDA) has reviewed its Investigational New Drug (IND) application for IkT-001Pro for the treatment of Chronic Myelogenous Leukemia (CML) and issued a Study May Procced (SMP) letter.
RTTNews
|
868天前
